GOAL: Multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin

Current Medical Research and Opinion

Volumn 26, Issue 5, 2010, Pages 1055-1063

  Pillai, Lakshmi ^a   Burnett, Bruce P ^a   Levy, Robert M ^a  

^a PRIMUS PHARMACEUTICALS INC   (United States)

Author keywords

5 lipoxygenase; Cyclooxygenase; Flavocoxid; Gastrointestinal; Limbrel; Osteoarthritis

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; DICLOFENAC; FLAVOCOXID; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; LIMBREL; MELOXICAM; NAPROXEN; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ADULT; ARTHRALGIA; ARTICLE; BLURRED VISION; CHILL; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; DISEASE SEVERITY; DIZZINESS; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; FEVER; FLATULENCE; FLUID RETENTION; FOLLOW UP; HEADACHE; HEARTBURN; HUMAN; HYPERTENSION; INSOMNIA; JOINT MOBILITY; JOINT STIFFNESS; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MULTICENTER STUDY; NAUSEA; OSTEOARTHRITIS; POSTMARKETING SURVEILLANCE; PRURITUS; QUALITY OF LIFE; RASH; RATING SCALE; SEDATION; SIDE EFFECT; VISUAL ANALOG SCALE; WHEEZING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATECHIN; DRUG COMBINATIONS; GASTROINTESTINAL TRACT; HUMANS; MOVEMENT; OSTEOARTHRITIS; PRODUCT SURVEILLANCE, POSTMARKETING; QUALITY OF LIFE;

EID: 77951031884     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003694522     Document Type: Article

References (64)

1. Burnett BP, Levy R, Cole BJ. Metabolic mechanisms in the pathogenesis of osteoarthritis. a review. J Knee Surg 2006;19:191-7
2. Paulus HE. FDA arthritis advisory committee meeting: serious gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs, etc. Arthritis Rheum 1988; 31:1450-1451
3. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-772
4. Cronberg S, Wallmark E, Soderberg I. Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol 1984;33:155-159
5. Lu HL. Statistical reviewer briefing document for the advisory committee. Celebrex NDA20-998
6. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006;116:4-15
7. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-1255
8. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997;112:1000-1016
9. Andrews FJ, Malcontenti-Wilson C, O'Brien PE. Effect of nonsteroidal anti-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa. Am J Physiol 1994;266:G657-64
10. Wallace JL, McKnight W, Reuter BK, et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119:706-714
11. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-1528
12. Stockl K, Cyprien L, Chang EY. Gastrointestinal bleeding rates among managed care patients newly started on COX-2 inhibitors or nonselective NSAIDs. J Manag Care Pharm 2005;11:550-558
13. Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002;324:1287-1288 (Pubitemid 34606764)
14. Zimmermann KC, Sarbia M, Schror K, et al. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol 1998;54:536-540
15. Baatar D, Jones MK, Pai R, et al. Selective cyclooxygenase-2 blocker delays healing of esophageal ulcers in rats and inhibits ulceration-triggered c-Met/hepatocyte growth factor receptor induction and extracellular signal-regulated kinase 2 activation. Am J Pathol 2002;160:963-972
16. Martel-Pelletier J. Proinflammatory mediators and osteoarthritis. Osteoarthr Cartil 1999;7:315-316
17. Martel-Pelletier J, Lajeunesse D, Reboul P, et al. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2003;62:501-509
18. Martel-Pelletier J, Mineau F, Fahmi H, et al. Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leuko-triene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids. Arthritis Rheum 2004;50:3925-3933
19. Hudson N, Balsitis M, Everitt S, et al. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993;34:742-747
20. Singh VP, Patil CS, Kulkarni SK. Effect of licofelone against NSAIDs-induced gastrointestinal ulceration and inflammation. Indian J Exp Biol 2005;43:247-253
21. Asako H, Kubes P, Wallace JL, et al. Indomethacin induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products. Am J Physiol 1992; 262:G903-8
22. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22
23. Burnett BP, Jia Q, Zhao Y, et al. A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation. J Med Food 2007;10:442-451
24. Levy R, Saikovsky R, Shmidt E, et al. Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study. Nutr Res 2009;29:298-304
25. Altavilla D, Squadrito F, Bitto A, et al. Flavocoxid, a dual inhibitor of cycloox-ygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin stimulated macrophages. Br J Pharmacol 2009;157:1410-1418
26. Vecka M, Prokes L, Tvrzicka E, et al. Anti-inflammatory activities of flavonoids from Comfort-G and the changes in arachidonic acid metabolism. Klin Biochem Metab 2008;16:27-32
27. Burnett BP, Silva S, Mesches MH, et al. Safety evaluation of a combination, defined extract of Scutellaria baicalensis and Acacia catechu. J Food Biochem 2007;31:797-825
28. Morgan SL, Baggott JE, Moreland L, et al. The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis. J Medicinal Foods 2008;12:1-6
29. Levy RM, Khokhlov A, Kopenkin S, et al. Efficacy and safety of flavocoxid: a novel therapeutic, compared with naproxen, in subjects with osteoarthritis of the knee. 2010:Submitted
30. Bent S, Padula A, Avins AL. Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med 2006;144:257-261 (Pubitemid 46768208)
31. Kaluzny JJ, Szaflik J, Czechowicz-Janicka K, et al. Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients. Acta Ophthalmol Scand 2003;81:349-354
32. Stewart WC, Day DG, Stewart JA, et al. Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs. placebo in primary open-angle glaucoma and ocular hypertension subjects. Eye (Lond) 2004;18:905-910
33. Day DG, Sharpe ED, Beischel CJ, et al. Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination. Eur J Ophthalmol 2005;15:336-342
34. Jones CW. A post-marketing surveillance study of Voltarol 75 mg SR in the primary care setting. Br J Clin Pract 1996;50:390-395
35. http://www.emea.europa.eu/humandocs/PDFs/EPAR/onsenal/370303en6.pdf
36. Moore RA, Derry S, Phillips CJ, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006;7:79
37. Butt JH, Barthel JS, Hosokawa MC, et al. NSAIDs: a clinical approach to the problems of gastrointestinal side-effects. Aliment Pharmacol Ther 1988;2 (Suppl 1):121-129
38. Walker AM, Chan KW, Yood RA. Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugs. J Clin Epidemiol 1992;45:187-195
39. Langman M, Kahler KH, Kong SX, et al. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Saf 2001;10:517-524
40. Leufkens HG, Ameling CB, Hekster YA, et al. Utilization patterns of non-steroidal anti-inflammatory drugs in an open Dutch population. Pharm Weekbl Sci 1990;12:97-103
41. Larkai EN, Smith JL, Lidsky MD, et al. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 1989;11:158-162
42. Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996;25:373-396
43. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol Suppl 1991;28:6-10
44. Smalley WE, Griffin MR, Fought RL, et al. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 1996;11:461-469
45. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gas-tropathy. Am J Med 1998;105:31-8S
46. Altman RD. Intra-articular sodium hyaluronate in osteoarthritis of the knee. Semin Arthritis Rheum 2000;30:11-18
47. Arroyo M, Lanas A. NSAIDs-induced gastrointestinal damage. Review. Minerva Gastroenterol Dietol 2006;52:249-259
48. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1366
49. Kimmey MB, Lanas A. Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors. Aliment Pharmacol Ther 2004;19(Suppl 1):60-65
50. Ofman JJ, Badamgarav E, Henning JM, et al. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis. Am J Med 2004;116:835-842
51. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996;156:1530-1536
52. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179:319-326
53. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-2953
54. Wright MJ, Proctor DD, Insogna KL, et al. Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev 2008;66:103-108
55. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000;95:3118-3122
56. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000;25:333-340
57. Pham CQ, Sadowski-Hayes LM, Regal RE. Prevalent prescribing of proton pump inhibitors: Prudent or pernicious? Pharm Ther 2006;31:159-167
58. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171:33-38
59. Carvajal A, Arias LH, Vega E, et al. Gastroprotection during the administration of non-steroidal anti-inflammatory drugs. A drug-utilization study. Eur J Clin Pharmacol 2004;60:439-444
60. Wright JM. The double-edged sword of COX-2 selective NSAIDs. CMAJ 2002; 167:1131-1137
61. Peskar BM. Role of leukotrience C4 in mucosal damage caused by necrotizing agents and indomethacin in the rat stomach. Gasteroenterology 1991; 100:619-626
62. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-235
63. Biswas K, Bandyopadhyay U, Chattopadhyay I, et al. A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem 2003;278:10993-11001
64. Lapenna D, De Gioia S, Mezzetti A, et al. H2-receptor antagonists are scavengers of oxygen radicals. Eur J Clin Invest 1994;24:476-481